Replimune Group (NASDAQ:REPL) Raised to Strong-Buy at Roth Capital

Roth Capital upgraded shares of Replimune Group (NASDAQ:REPL) to a strong-buy rating in a research note issued to investors on Tuesday morning, Zacks.com reports. Roth Capital also issued estimates for Replimune Group’s Q2 2025 earnings at ($0.87) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.90) EPS, FY2025 earnings at ($3.43) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.65) EPS, FY2027 earnings at ($2.65) EPS, FY2028 earnings at ($1.52) EPS and FY2029 earnings at ($0.40) EPS.

Other equities research analysts also recently issued research reports about the company. HC Wainwright upped their target price on Replimune Group from $12.00 to $17.00 and gave the stock a buy rating in a research report on Friday, June 7th. JPMorgan Chase & Co. decreased their price target on Replimune Group from $17.00 to $14.00 and set an overweight rating for the company in a report on Tuesday, August 13th. Barclays increased their price objective on shares of Replimune Group from $13.00 to $17.00 and gave the company an overweight rating in a research report on Friday, June 7th. Wedbush restated an outperform rating and set a $16.00 target price on shares of Replimune Group in a research note on Thursday, June 6th. Finally, Roth Mkm initiated coverage on Replimune Group in a research note on Tuesday. They issued a buy rating and a $17.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus target price of $16.20.

Replimune Group Trading Down 8.0 %

Shares of REPL stock opened at $10.17 on Tuesday. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $21.32. The firm’s 50 day moving average price is $9.73 and its two-hundred day moving average price is $8.17. The stock has a market cap of $624.59 million, a price-to-earnings ratio of -3.14 and a beta of 1.25.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. On average, analysts anticipate that Replimune Group will post -3.08 EPS for the current year.

Insider Buying and Selling at Replimune Group

In related news, insider Konstantinos Xynos sold 15,881 shares of Replimune Group stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $7.50, for a total value of $119,107.50. Following the completion of the transaction, the insider now directly owns 117,131 shares in the company, valued at $878,482.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Konstantinos Xynos sold 15,881 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $7.50, for a total transaction of $119,107.50. Following the sale, the insider now directly owns 117,131 shares of the company’s stock, valued at approximately $878,482.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares in the company, valued at $1,028,760.26. The disclosure for this sale can be found here. 20.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently made changes to their positions in REPL. Price T Rowe Associates Inc. MD increased its holdings in shares of Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after acquiring an additional 699,679 shares during the period. Millennium Management LLC increased its stake in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after purchasing an additional 2,656,173 shares during the period. Vanguard Group Inc. raised its holdings in shares of Replimune Group by 1.2% during the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after buying an additional 32,555 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Replimune Group by 300.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock worth $18,874,000 after buying an additional 1,679,553 shares during the period. Finally, Rafferty Asset Management LLC grew its holdings in Replimune Group by 148.1% in the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after buying an additional 276,596 shares in the last quarter. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.